2b乔巴发琴无力罗宾彩色_日韩欧美理论一级片_日韩欧美中文字幕在_韩国三级在线不卡播放_美女靠逼软件_99无码蜜臀人妻久久精品_九九精品亚洲视频_国产大学生闺蜜AV在线播放_主人给我戴上奶牛榨乳器调教_被灌满精子的波多野结衣

One more step in Kexing Biopharm's R&D!

On the evening of August 14, 2022, Kexing Biopharm Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that it had recently received the Notice of Acceptance, an administrative license document issued by the National Medical Products Administration (hereinafter referred to as "NMPA"), indicating that its clinical trial application for "Human Interferon α2b Spray" was accepted.

Basic Information of the Drug for Registration

1.  Product Name: Human Interferon α2b Spray
2. Application Item: clinical trial for registration of drugs produced in China
3. Acceptance No.: CXSL2200374G
4. Indication: It is proposed for the treatment of initial or recurrent skin herpes simplex (oral herpes and genital herpes) caused by virus.
5. Dosage Form: spray

The promotion of the R&D of Human Interferon α2b Spray will help the Company further optimize the product portfolio, enrich the product pipelines, enhance the overall R&D capability, and build up the long-term profitability.

About Human Interferon α2b Spray
Human Interferon α2b Spray is a Class 2 modified new drug, independently developed by the Company, with optimized dosage form and administration route compared with the drugs already on the market. It has the obvious clinical advantages of increased drug concentration at the lesions through targeted local administration, convenient use and carrying, and good patient compliance. The Human Interferon α2b Spray is indicated for the treatment of initial or recurrent skin herpes simplex (oral herpes and genital herpes) caused by virus.